EZH2 and myeloproliferative neoplasm: Mouse models of MPN have also shown that EZH2 plays a tumor suppressive role in PMF, as additional deletion of EZH2 in mice carrying the activating JAK2 V617F mutation promotes the development and progression of myelofibrosis, resulting in reduced survival, increased platelet and neutrophil counts and more advanced disease [65].